Andrew James King - Feb 10, 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC. (KDNY)

Role
Chief Scientific Officer
Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Stock symbol
KDNY
Transactions as of
Feb 10, 2022
Transactions value $
-$32,400
Form type
4
Date filed
2/11/2022, 04:26 PM
Previous filing
Feb 2, 2022
Next filing
Feb 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KDNY Common Stock Options Exercise $875 +2.5K +61.06% $0.35* 6.59K Feb 10, 2022 Direct
transaction KDNY Common Stock Sale -$33.3K -2.5K -37.91% $13.31 4.09K Feb 10, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Stock Option (right to buy) Options Exercise $0 -2.5K -3.54% $0.00 68K Feb 10, 2022 Common Stock 2.5K $0.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The stock option vested as to 25% of the total shares on May 6, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.